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Abstract: Background: The value of routine aminoterminal pro type B natriuretic peptide (NT-proBNP) measurements in 
outpatient clinics remains unknown.  
Objectives: We sought to determine the accuracy with which heart failure (HF) specialists can predict NT-proBNP levels 
in HF outpatients based on clinical assessment. 
Methods: We prospectively studied 160 consecutive HF patients followed in an outpatient multidisciplinary HF clinic. 
During a regular office visit, HF specialists were asked to estimate a patient’s current NT-proBNP level based upon their 
clinical assessment and all available information from their chart, including a previous NT-proBNP level (if available). 
NT-proBNP estimations were grouped into prognostic categories (<125, 125-1000, 1000-4998, or 4999 pg/mL) and 
comparisons made between actual and estimate values.  
Results: Overall, HF specialists estimated 67.5% of NT-proBNP levels correctly. After adjusting for clinical characteris-
tics, knowledge of a prior NT-proBNP measurement was the only significant predictor of estimation accuracy (p=0.01). 
Compared to patients with a prior NT-proBNP level <125 pg/mL, physicians were 95% less likely to get a correct 
estimation in patients with the highest prior NT-proBNP level (4999 pg/mL).  
Conclusion: HF specialists are reasonably accurate at estimating current NT-proBNP levels based upon clinical assess-
ment and a previous NT-proBNP level, if those levels were < 4999 pg/mL.  Likely, initial but not routine NT-proBNP 
measurements are useful in outpatient HF clinics.  
INTRODUCTION 
B-type natriuretic peptide (BNP) is released from ven-
tricular myocardial tissue in response to increased wall 
stress. Both BNP and aminoterminal pro-type B natriuretic 
peptide (NT-proBNP), an inactive amino acid product of 
BNP prohormone cleavage, can be measured in the serum 
and both are typically elevated in heart failure (HF).  
NT-proBNP is frequently measured at regular intervals in 
HF outpatients. Multiple studies have demonstrated the value 
of NT-proBNP in the diagnosis of congestive HF [1-6]. Re-
cent research suggests that serial NT-proBNP measurements 
may also have a role in prognostic evaluation [7-12] and 
therapy optimization [13-16]. To date, however, studies have 
not been conducted looking at the cost-effectiveness of regu-
lar outpatient NT-proBNP measurements. Further, in the 
2007 Canadian Cardiovascular Society Consensus Confer-
ence recommendations on HF, sequential measurements of  
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BNP/NT-proBNP levels were given a class IIb recommenda-
tion [17].  
Skepticism remains regarding the value of routine NT-
proBNP measurements in outpatient clinics. Specifically, it 
is unknown whether clinicians are able to accurately predict 
NT-proBNP levels on an outpatient basis. Our primary ob-
jective was to determine the accuracy with which HF spe-
cialists can predict NT-proBNP levels in HF patients based 
on clinical assessment during an office visit. Our secondary 
objective was to determine whether certain clinical charac-
teristics (i.e., gender, BMI, age, eGFR, NYHA, and the 
absence of a previous NT-proBNP level) were predictors of 
accurate NT-proBNP estimations.  
METHODS 
Patient Characteristics and Study Protocol 
We enrolled 160 consecutive patients >18 years with 
known HF attending the outpatient Heart Function, Post-
Heart Transplant, and Maintenance Clinics at St. Paul's Hos-
pital in Vancouver, British Columbia, Canada. Ethics ap-
proval for the study was obtained from the University of 
British Columbia/Providence Health Care Research Ethics 
Board. NT-proBNP levels were drawn from each HF patient 
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of five HF specialists as a regular office visit. All HF spe-
cialists were cardiologists trained specifically in HF and all 
patients were seen in St. Paul’s Hospital, a high volume ter-
tiary care center. During this visit, physicians were asked to 
estimate the patient's current NT-proBNP level based upon 
their clinical assessment and all available information from 
the patient's chart, including a previous NT-proBNP level (if 
available). Actual and estimated NT-proBNP levels were 
then recorded by an independent physician, in addition to 
gender, age, previous NT-proBNP level (if available), cur-
rent body mass index (BMI), most recent glomerular filtra-
tion rate (eGFR), and current New York Heart Association 
(NYHA) class. NT-proBNP levels  were grouped into prog-
nostic categories (<125, 125-1000, 1000-4998 or 4999 
pg/mL) outlined by a recent study by Rothenburger et al. 
[10]. If the estimated and the actual NT-proBNP prognostic 
categories were the same, we considered this as an accurate 
estimation. 
NT-proBNP Measurement 
NT-proBNP levels were measured by the Elecsys® 
proBNP immunoassay on the Roche Elecsys® 1010 immu-
noassay analyzer. 
Statistical Analyses 
For univariate analysis, the Chi-square test was used to 
examine the association between correct physician NT-
proBNP estimation and the following factors: gender, BMI 
<25 kg/m
2, age <65, eGFR>60 mL/min./1.73m
2, NYHA 
class I or II, the absence of a previous NT-proBNP meas-
urement, and the category of the most recent prior NT-
proBNP level (if available). For multivariable analysis, a 
logistic regression model was used to investigate the associa-
tion between the prior NT-proBNP prognostic category and 
correct physician NT-proBNP estimation, adjusted for gen-
der, BMI, age, eGFR, NYHA, and the time difference be-
tween the current test and prior test. 
RESULTS 
Baseline characteristics of the patients are displayed in 
Table 1. In general, more patients were male (69.5%), less 
than 65 years of age (56.1%), had an elevated BMI  25 
(76.2%), were NYHA I or II (76.4%), and had a previous 
NT-proBNP (82.3%). Most patients with a previous NT-
proBNP level had a measurement between 1000-4998 pg/mL 
and a time interval between measurements of 6 to 12 
months. 
Overall, HF specialists estimated 67.5% of NT-proBNP 
levels correctly. In univariate analysis, a prior NT-proBNP 
measurement was significantly  associated with estimation 
accuracy (p=0.01). Importantly, the level of prior NT-
proBNP measurement was significantly associated with es-
timation accuracy (p=0.002). For patients with a prior NT-
proBNP test, physician estimations were good for patients 
with a prior BNP level <125 pg/mL (92.3%) and BNP levels 
between 125-999 pg/mL (84.2%), but the accuracy reduced 
greatly as the prior NT-proBNP levels increased. The correct 
estimation was only 66.7% in patients with a prior BNP level 
between 1000 and 4998 pg/mL. The accuracy of physician 
estimations for patients with a prior NT-proBNP level 4999 
further reduced to 47.1%, which was similar to that of pa-
tients without a prior NT-proBNP test (46.2%). No signifi-
cant association was observed for any other factors. 
Table 1.  Baseline Characteristics of HF Patients 
Characteristic n  % 
Female 50  30.5 
BMI  25 kg/m
2 125  76.2 
Age  65 years  72  43.9 
eGFR60 mL/min./1.73m
2 85  51.8 
NYHA III/IV  38  23.6 
Prior NT-proBNP measurement  135  82.3 
Time from last measurement     
<6month 39  28.9 
6 month to 12 month  61  45.2 
12 month  35  25.9 
Prior NT-proBNP level (pg/mL)     
<125 13  9.6 
125-1000 42  31.1 
1000-4999 63  46.7 
4999 17  12.6 
BMI = body mass index; eGFR = glomerular filtration rate; NYHA = New York Heart 
Association; NT-proBNP = aminoterminal pro type B natriuretic peptide.  
 
The results of multivariable analysis echoed that of the 
univariate analysis. The absence of a prior NT-proBNP 
measurement significantly reduced the accuracy of physician 
estimation (OR: 0.05; 95%CI 0.004-0.49) (Table 2). The 
level of prior NT-proBNP also greatly affected the estima-
tion accuracy. Compared to patients with a prior NT-proBNP 
level <125 pg/mL, physicians were 95% less likely to get a 
correct estimation, in patients with the highest prior NT-
proBNP level (4999 pg/mL). This was after adjustment for 
gender, BMI, age, GFR, NYHA, and the time difference 
between the current and prior test. 
DISCUSSION 
We found that HF specialists are relatively accurate at es-
timating NT-proBNP prognostic categories based upon clini-
cal assessment and a previous NT-proBNP level. They are 
less accurate at predicting NT-proBNP levels in new patients 
with no prior NT-proBNP measurement and in patients with 
a prior NT-proBNP level 4999 pg/mL. Renal insufficiency, 
NYHA class, BMI, gender, and age do not appear to be pre-
dictive markers of accurate NT-proBNP estimations. To our 
knowledge, we are the first group to establish that perhaps 
initial but not routine NT-proBNP measurements may be 
useful in outpatients whose initial measurements were < 
4999 pg/mL.  
NT-proBNP/BNP in the Diagnosis, Prognostic Evalua-
tion, and Management of Patients with CHF 
To date, NT-proBNP/BNP has been studied in a variety 
of clinical settings. In the diagnosis of congestive HF, the 38    The Open Cardiovascular Medicine Journal, 2008, Volume 2  Sedlak et al. 
 
use of NT-proBNP and BNP measurement in the emergency 
department has been well established [5,6]. In contrast, the 
use of neurohormones in the outpatient diagnosis of HF has 
been less well studied. In a study by Groenning et al., NT-
proBNP measurement in the outpatient setting identified 
patients with symptoms of HF and a low left ventricular 
ejection fraction (LVEF) of less than 40% with a positive 
predictive value of 0.11 and a negative predictive value of 
1.00 [4]. In a study by Wright et al. that recruited patients 
presenting to their general practitioner with dyspnea and/or 
edema, knowledge of the NT-proBNP level improved the 
diagnostic accuracy of heart failure from 8% (control group) 
to 21% (NT-proBNP group) (p=0.002)
  [3].  Finally, 
Zaphiriou et al. performed a study on 306 patients referred to 
a heart failure clinic by their general practitioners with sus-
pected heart failure. They found that NT-proBNP and BNP 
were good rule-out tests with high negative predictive values 
(0.97 and 0.87, respectively) but low positive predictive val-
ues (0.44 and 0.59, respectively)
 [2]. 
Recent research suggests that serial NT-proBNP meas-
urements may have a role in prognostic evaluation [7-12] 
and therapy optimization [13-16]. In prognostic evaluation, 
NT-proBNP/BNP has been found to be an independent pre-
dictor of sudden death [7], HF hospital admissions [4], and 
depressed left ventricular function [7]. In a recent systematic 
review of 19 studies using BNP to estimate the relative risk 
of death or cardiovascular events in HF patients, BNP was 
found to be a strong prognostic indicator [18]. Each 100 
pg/mL increase in BNP was associated with a 35% increase 
in the relative risk of death. Further, Maisel et al. in the 
Rapid Emergency Department Heart Failure Outpatient Trial 
(REDHOT) study found that BNP is a potent predictor of the 
90-day combined event rate of congestive HF visits or ad-
missions and mortality in patients admitted from the emer-
gency department with acute HF [19]. In the Valsartan Heart 
Failure Trial, HF patients with an initial BNP level greater 
than 97 pg/mL were 2.1 times more likely to die at 12 
months [20]. As well, in the Australia/New Zealand Heart 
Failure Study, BNP was superior to LVEF in predicting mor-
tality and HF in patients with ischemic LV dysfunction [9]. 
Above-median BNP levels conferred a 3-fold-increased risk 
of mortality. In pre-heart transplant assessment [10], an arbi-
trary cutoff point of >2000 pg/mL for patients with dilated 
cardiomyopathy and >1000 pg/mL for patients with LV dys-
function secondary to coronary artery disease included 90% 
of all patients who were clinically considered for cardiac 
transplantation. As well, BNP appears to be useful in pre-
dicting the progression of HF after cardiac resynchronization 
therapy (CRT) [21]. Specifically, patients with high BNP 
values after 1 month of CRT have worse prognosis during 
follow-up.  
Finally, in therapy optimization, Troughton et al. demon-
strated that titration of therapy guided by NT-proBNP levels 
in symptomatic HF patients decreased hospital re-admission 
rates and cardiac mortality at 9.5 months follow-up, as com-
pared to conventional follow up [14]. BNP may guide the 
introduction of medications in HF. Richards et al. demon-
strated that carvedilol reduced mortality rates in HF to a 
greater extent in patients with higher pretreatment BNP lev-
Table 2.  Adjusted Odds Ratios of Correct Estimation of Current NT-proBNP Category 
Factors  Odds Ratio  95% CI  p-value 
No prior NT-proBNP measurement  0.05  (0.004,0.49)  0.01 
Time from last measurement       
 12 months  1.00     
6-12 months  0.67  (0.219,2.062)  0.48 
<6 months  0.57  (0.177,1.851)  0.35 
Prior NT-proBNP level (pg/mL)       
<125 1.00     
125-999 0.15  (0.016,1.377)  0.09 
1000-4998 0.48  (0.049,4.686)  0.53 
4999    0.05  (0.004,0.605)  0.02 
Female 0.82  (0.364,1.864)  0.64 
BMI   25 kg/m
2 1.16  (0.456,2.958)  0.75 
Age   65   1.03  (0.424,2.515)  0.94 
eGFR  60 mL/min./1.73m
2 0.53  (0.191,1.483)  0.23 
NYHA class   III/IV  0.69  (0.288,1.657) 0.41 
BMI = body mass index; eGFR = glomerular filtration rate; NYHA = New York Heart Association; NT-proBNP = aminoterminal pro type B natriuretic peptide.  The Ability of Heart Failure Specialists to Accurately Predict NT-proBNP  The Open Cardiovascular Medicine Journal, 2008, Volume 2    39 
 
els (9). More recently, in the Systolic Heart Failure Treat-
ment Supported By BNP (STARS-BNP) Multicenter Ran-
domized Trial patients randomized to the BNP guided treat-
ment group suffered fewer events (death or hospitalizations) 
for HF than in the control group (p<0.001) [16]. 
The above studies suggest that knowledge of an initial 
NT-proBNP and perhaps repeat NT-proBNP levels may 
guide diagnosis, prognosis and therapy management. The 
most recent HF guidelines, specifically, the 2007 Canadian 
Cardiovascular Society Consensus Conference Recommen-
dations on Heart Failure, support the initial measurement of 
NT-proBNP/BNP for diagnosis (class I recommendation) 
and prognostic stratification (class IIa recommendation). The 
guidelines do not however support sequential measurements 
of BNP/NT-proBNP levels in the outpatient setting (class IIb 
recommendation) [17]. To date, no study has demonstrated 
that routine measurement of NT-proBNP levels in the outpa-
tient setting is cost-effective. In our study, HF specialists 
were relatively accurate at estimating NT-proBNP levels 
when a prior NT-proBNP measurement was available, irre-
spective of the time interval between measurements. In con-
trast, they were less accurate at predicting NT-proBNP levels 
in new patients with no prior NT-proBNP level and in pa-
tients with patients with a prior NT-proBNP level 4999 
pg/mL.  
Predictors of NT-proBNP Estimation Accuracy 
Recent studies suggest that NT-proBNP levels are altered 
in overweight individuals. Specifically, NT-proBNP levels 
are significantly lower in overweight and obese individuals 
with HF compared with lean patients [22,23]. Age and gen-
der alter NT-proBNP levels. Redfield et al. found in a recent 
study that BNP increased significantly with age and was 
higher in women than men [24]. Renal dysfunction also al-
ters NT-proBNP levels in that eGFR and BNP are inversely 
related [25].  
We hypothesized that age >65 years, female gender, ele-
vated BMI (>25 kg/m
2), renal dysfunction (eGFR <60 
mL/min./1.73m
2), NYHA class I or II, and absence of a prior 
NT-proBNP level would be predictive of NT-proBNP esti-
mation accuracy. Surprisingly, we found that a prior NT-
proBNP measurement was the only factor significantly 
associated with the accuracy of physician estimation. Age 
>65 years, female gender, elevated BMI (>25 kg/m
2), renal 
dysfunction (eGFR <60 mL/min./1.73m
2), NYHA class I or 
II were not associated with accurate NT-proBNP estima-
tions. In our study, physicians had access to all patient re-
cords in the heart failure clinic, including GFR, BMI, etc. 
We believe that HF specialists purposefully altered their NT-
proBNP estimation as a result of this knowledge enabling 
them to guess correctly.  
Interestingly, in patients with a prior NT-proBNP level, 
accuracy reduced greatly as the prior NT-proBNP levels in-
creased. Compared to patients with a prior NT-proBNP level 
<125 pg/mL, physicians were 95% less likely to get a correct 
estimation, in patients with the highest prior NT-proBNP 
level (4999 pg/mL). Karabulut et al. found that while NT-
proBNP levels increase significantly with each increasing 
class of disease, there is a wider range of NT-proBNP levels 
in NYHA classes III and IV [26]. This may account for our 
relative inaccuracy at estimating NT-proBNP levels in 
higher NYHA classes. In these patients, it may be useful to 
measure NT-proBNP levels on a more routine basis. 
CONCLUSIONS 
In conclusion, we found that heart failure specialists are 
fairly accurate at predicting NT-proBNP levels in heart fail-
ure patients only if a prior NT-proBNP measurement is 
available and the prior level was < 4999 pg/mL. In these 
patients, likely, initial but not routine measurements of NT-
proBNP are useful in outpatient heart failure clinics. 
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